CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  

Core Curriculum on Tuberculosis, 2000

Chapter 7
Treatment of TB Disease

Endnotes

  1. Centers for Disease Control and Prevention. Program Management Reports. Unpublished data.
  2. Mushlin AI, Appel FA. Diagnosing potential noncompliance. Arch Intern Med 1977;137:318-321.
  3. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1998. August 1999.
  4. Burman WJ, Dalton CB, Cohn DL, Butler JRG, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997;112:63-70.
  5. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996;154:1013-1019.
  6. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330(17);1179-1184.
  7. McDonald RJ, Memon AM, Reichman LB. Successful supervised ambulatory management of tuberculosis treatment failures. Ann Intern Med 1982;96:297-302.
  8. Combs DL, O’Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397-406.
  9. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990;112:407-415.
  10. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987;136:1339-1342.
  11. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians’ seven-year experience with mainly outpatients. Am J Med 1984;77:233-242.
  12. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 1989;139:871- 876.
  13. Dutt AK, Moers D, Stead WW. Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy. Am Rev Respir Dis 1989;139:867- 870.
  14. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines on the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(No. RR-5):1-63.
  15. Strang JIG, Kakaza HHS, Gibson DG, et al. Controlled trial of prednisone as adjunct in treatment of tuberculosis constrictive pericarditis in Trankei. Lancet 1987;2:1418-1422.
  16. Girgis NI, Farid Z, Kilpatrick ME, et al. Dexamethasone as an adjunct to treatment of tuberculosis meningitis. Ped Infect Dis J 1991;10:179-183.
  17. Trébucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997;1:12-15.
  18. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:579-85.
  19. Zierski M. Prospects of retreatment of chronic resistant pulmonary tuberculosis patients: a critical review. Lung 1977;154:91- 102.
  20. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329(11):784-791.
  21. Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:623-625.
  22. Tuberculosis Chemotherapy Centre, Madras. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis. II. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull WHO 1963;29:457-481.
  23. Krishnamurthy DV, Selkon JB, Ramachandran K, et al. Effect of pyridoxine on vitamin B6 concentrations and glutamic-oxaloacetic transaminase activity in whole blood of tuberculous patients receiving high-dosage isoniazid. Bull WHO 1967;36:853-870.
  24. Selwyn PA. Medical aspects of human immunodeficiency virus infection and its treatment in injecting drug users. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance Abuse: A Comprehensive Textbook. 2nd ed. Baltimore: Williams & Wilkins; 1992:744-774.

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333